Falcon

Pharma

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 2 drugs with upcoming expirations

Activity

Key Events

May 28, 2025FDATryptyr — TRYPTYR

Dec 18, 2017FDARhopressa — RHOPRESSA

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

5 patent groups across drugs · Source: FDA Orange Book

DrugExpires

Rhopressa3 patentsJul 11, 2026 Rhopressa2 patentsJan 27, 2030 Tryptyr3 patentsSep 8, 2031 RhopressaMar 14, 2034 Tryptyr2 patentsDec 16, 2042

Regulatory

Regulatory Timeline

19823 events

FDAJan 1

Mydriacyl — MYDRIACYL

Application NDA012111 (NDA)

FDAJan 1

Funduscein-25 — FUNDUSCEIN-25

Application NDA017869 (NDA)

FDAJan 1

Miostat — MIOSTAT

Application NDA016968 (NDA)

20001 event

FDAFeb 23

Betaxon — BETAXON

Application NDA021114 (NDA)

20061 event

FDAMar 28

Funduscein-25 — FLUORESCITE

Application NDA021980 (NDA)

20081 event

FDAAug 8

Funduscein-25 — AK-FLUOR 10%

Application NDA022186 (NDA)

20171 event

FDADec 18

Rhopressa — RHOPRESSA

Application NDA208254 (NDA)

20251 event

FDAMay 28

Tryptyr — TRYPTYR

Application NDA217370 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)